Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.22 USD

17.22
1,319,063

-0.27 (-1.54%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $17.21 -0.01 (-0.06%) 7:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Exact Sciences (EXAS) Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences' (EXAS) better-than-expected results and robust Cologuard volumes.

Zacks Equity Research

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks Equity Research

Medtronic (MDT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic (MDT) posts better-than-expected results for the fiscal first quarter and maintains earnings and sales outlook for the full year.

Zacks Equity Research

3 Reasons to Hold OPKO Health (OPK) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in Rayaldee.

Zacks Equity Research

Here's Why You Should Buy McKesson (MCK) Stock Right Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Zacks Equity Research

Zacks.com featured highlights include AMN Healthcare, Encore Wire, Veritiv and SP Plus

by Zacks Equity Research

AMN Healthcare, Encore Wire, Veritiv and SP Plus have been highlighted in this Screen of The Week article.

Zacks Equity Research

Here's Why You Should Invest in Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) better-than-expected results and continued growth across major geographies.

Zacks Equity Research

Thermo Fisher (TMO) to Offer Wheat & Sesame Allergy Testing

by Zacks Equity Research

Thermo Fisher's (TMO) ImmunoCAP blood tests receive FDA approval for wheat and sesame allergy diagnosis.

Zacks Equity Research

Here's Why You Should Buy ShockWave Medical (SWAV) Stock

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D efforts and commitment to clinical studies.

Zacks Equity Research

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

by Zacks Equity Research

NextGen's (NXGN) solid product portfolio and continued demand for its solutions raise optimism about the stock.

Moumita C. Chattopadhyay headshot

4 High-Flying Stocks With Rising Cash Flows to Buy Now

by Moumita C. Chattopadhyay

Companies with rising cash flows like AMN, WIRE, VRTV and SP are worth buying.

Zacks Equity Research

Zacks.com featured highlights include AMN Healthcare, Earthstone Energy and Hanmi Financial

by Zacks Equity Research

AMN Healthcare, Earthstone Energy and Hanmi Financial have been highlighted in this Screen of The Week article.

Zacks Equity Research

QIAGEN's (QGEN) New Syndromic Test to Combat Monkeypox Spread

by Zacks Equity Research

QIAGEN (QGEN) joins the global fight against monkeypox with the launch of its novel QIAstat-Dx Viral Vesicular Panel RUO.

Zacks Equity Research

Here's Why You Should Hold on to Catalent (CTLT) Stock Now

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism about the stock.

Zacks Equity Research

Teleflex (TFX) Hit by Urolift Volume Decline, Cost Pressure

by Zacks Equity Research

In the Americas, growth within the Surgical business of Teleflex (TFX) is offset by a decline in Interventional Urology.

Zacks Equity Research

Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.

Zacks Equity Research

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Tirthankar Chakraborty headshot

3 Top-Rated Momentum Stocks to Buy Using Driehaus Strategy

by Tirthankar Chakraborty

Stocks like AMN Healthcare Services (AMN), Earthstone Energy (ESTE) and Hanmi Financial (HAFC) have been selected as the momentum picks for the day using the Driehaus strategy.

Zacks Equity Research

3 Reasons Why AMN Healthcare (AMN) Is a Great Growth Stock

by Zacks Equity Research

AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision

by Zacks Equity Research

Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.

Zacks Equity Research

Here's Why Investors Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) better-than-expected results and expanded Panther installed base.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to boost the top line further.

Zacks Equity Research

IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints

by Zacks Equity Research

The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.

Zacks Equity Research

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

BD's (BDX) Latest Collaboration to Boost Patient Outcome

by Zacks Equity Research

BD's (BDX) tie-up with Accelerate Diagnostics is expected to strengthen the fight to combat the global threat of antimicrobial resistance, thereby boosting patient care.